(SENS) Senseonics Holdings, Common - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NYSE MKT (USA) | Currency USD | Market Cap: 274m | Total Return -50% in 12m

Stock: Implantable, Glucose, Sensor, Transmitter, App

Total Rating 11
Risk 30
Buy Signal -1.28
Medical Devices -6.0
Health Care Supplies -12.1
Market Cap: 274m
Avg Trading Vol: 3.22M USD
ATR: 7.26%
Peers RS (IBD): 6.3
Risk 5d forecast
Volatility 75.8%
Relative Tail Risk -14.7%
Reward TTM
Sharpe Ratio -0.76
Alpha -70.97
Character TTM
Beta 1.436
Beta Downside 2.240
Drawdowns 3y
Max DD 79.89%
CAGR/Max DD -0.29

EPS (Earnings per Share)

EPS (Earnings per Share) of SENS over the last years for every Quarter: "2021-03": -0.68, "2021-06": -0.42, "2021-09": 0.08, "2021-12": 0.21, "2022-03": -0.03, "2022-06": -0.03, "2022-09": -0.13, "2022-12": 0.02, "2023-03": -0.04, "2023-06": -0.04, "2023-09": -0.04, "2023-12": -0.03, "2024-03": -0.03, "2024-06": -0.03, "2024-09": -0.04, "2024-12": -0.02, "2025-03": -0.02, "2025-06": -0.4, "2025-09": -0.43, "2025-12": -0.46,
EPS CAGR: -72.34%
EPS Trend: -63.8%
Last SUE: -2.40
Qual. Beats: 0

Revenue

Revenue of SENS over the last years for every Quarter: 2021-03: 2.846, 2021-06: 3.289, 2021-09: 3.532, 2021-12: 4.008, 2022-03: 2.481, 2022-06: 3.714, 2022-09: 4.622, 2022-12: 5.571, 2023-03: 4.137, 2023-06: 4.126, 2023-09: 6.097, 2023-12: 8.03, 2024-03: 5.047, 2024-06: 4.865, 2024-09: 4.263, 2024-12: 8.297, 2025-03: 6.257, 2025-06: 8.297, 2025-09: 8.095, 2025-12: 14.256,
Rev. CAGR: 59.40%
Rev. Trend: 79.2%
Last SUE: 0.08
Qual. Beats: 0

Risks

Technicals: volatile

Description: SENS Senseonics Holdings, Common March 03, 2026

Senseonics Holdings, Inc. (NYSE MKT: SENS) is a commercial-stage medical-technology firm that designs, manufactures, and markets implantable continuous glucose monitoring (CGM) systems-including Eversense, Eversense XL, Eversense E3, and Eversense 365-for diabetes management in the U.S. and abroad. The platform combines an under-skin sensor, a rechargeable smart transmitter, and a mobile app, and is distributed through a network of healthcare providers, distributors, and fulfillment partners. Founded in 1996, the company is headquartered in Germantown, Maryland, and operates within the Health Care Supplies sub-industry.

Recent data highlights several key drivers: (1) Q2 2024 revenue reached $22.1 million, a 14% year-over-year increase driven by expanding Eversense XL adoption; (2) the global CGM market is projected to grow at a CAGR of ~12% through 2030, fueled by rising diabetes prevalence (≈13% of U.S. adults) and reimbursement improvements; and (3) Senseonics secured a new FDA clearance in January 2024 for a longer-life sensor, extending wear time to 180 days, which could boost market share against competitors like Dexcom and Abbott.

For a deeper, data-rich analysis of SENS and its valuation dynamics, you may find ValueRay’s research platform worth exploring.

Headlines to watch out for

  • Eversense CGM system adoption drives revenue growth
  • Regulatory approvals for new products impact market access
  • Reimbursement policies for CGM systems affect sales
  • Manufacturing costs and supply chain efficiency influence profitability
  • Competition from other CGM providers pressures market share

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -70.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.52 > 0.02 and ΔFCF/TA 10.85 > 1.0
NWC/Revenue: 252.5% < 20% (prev 234.0%; Δ 18.48% < -1%)
CFO/TA -0.47 > 3% & CFO -59.1m > Net Income -70.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.83 > 1.5 & < 3
Outstanding Shares: last quarter (41.7m) vs 12m ago 25.16% < -2%
Gross Margin: 44.96% > 18% (prev 0.02%; Δ 4.49k% > 0.5%)
Asset Turnover: 32.56% > 50% (prev 22.37%; Δ 10.18% > 0%)
Interest Coverage Ratio: -4.49 > 6 (EBITDA TTM -53.5m / Interest Expense TTM 12.6m)

Altman Z'' -15.00

A: 0.74 (Total Current Assets 117.5m - Total Current Liabilities 24.3m) / Total Assets 126.3m
B: -8.05 (Retained Earnings -1.02b / Total Assets 126.3m)
C: -0.50 (EBIT TTM -56.5m / Avg Total Assets 113.4m)
D: -15.59 (Book Value of Equity -1.02b / Total Liabilities 65.2m)
Altman-Z'' Score: -41.14 = D

Beneish M -3.76

DSRI: 0.94 (Receivables 12.4m/8.08m, Revenue 36.9m/22.5m)
GMI: 0.05 (GM 44.96% / 2.37%)
AQI: 0.67 (AQ_t 0.04 / AQ_t-1 0.05)
SGI: 1.64 (Revenue 36.9m / 22.5m)
TATA: -0.09 (NI -70.1m - CFO -59.1m) / TA 126.3m)
Beneish M-Score: -3.76 (Cap -4..+1) = AAA

What is the price of SENS shares?

As of March 30, 2026, the stock is trading at USD 6.56 with a total of 439,017 shares traded.
Over the past week, the price has changed by -0.91%, over one month by -20.68%, over three months by +15.70% and over the past year by -50.00%.

Is SENS a buy, sell or hold?

Senseonics Holdings, Common has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold SENS.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the SENS price?

Issuer Target Up/Down from current
Wallstreet Target Price 18.9 188.4%
Analysts Target Price 18.9 188.4%

SENS Fundamental Data Overview March 29, 2026

P/E Forward = 21.0084
P/S = 7.7719
P/B = 4.4202
Revenue TTM = 36.9m USD
EBIT TTM = -56.5m USD
EBITDA TTM = -53.5m USD
Long Term Debt = 35.6m USD (from longTermDebt, last quarter)
Short Term Debt = 496k USD (from shortTermDebt, last quarter)
Debt = 41.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 822k USD (from netDebt column, last quarter)
Enterprise Value = 221.4m USD (274.0m + Debt 41.4m - CCE 94.0m)
Interest Coverage Ratio = -4.49 (Ebit TTM -56.5m / Interest Expense TTM 12.6m)
EV/FCF = -3.40x (Enterprise Value 221.4m / FCF TTM -65.1m)
FCF Yield = -29.43% (FCF TTM -65.1m / Enterprise Value 221.4m)
FCF Margin = -176.5% (FCF TTM -65.1m / Revenue TTM 36.9m)
Net Margin = -189.9% (Net Income TTM -70.1m / Revenue TTM 36.9m)
Gross Margin = 44.96% ((Revenue TTM 36.9m - Cost of Revenue TTM 20.3m) / Revenue TTM)
Gross Margin QoQ = 53.79% (prev 42.84%)
Tobins Q-Ratio = 1.75 (Enterprise Value 221.4m / Total Assets 126.3m)
Interest Expense / Debt = 18.92% (Interest Expense 7.83m / Debt 41.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.6m (EBIT -56.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.83 (Total Current Assets 117.5m / Total Current Liabilities 24.3m)
Debt / Equity = 0.68 (Debt 41.4m / totalStockholderEquity, last quarter 61.0m)
Debt / EBITDA = -0.02 (negative EBITDA) (Net Debt 822k / EBITDA -53.5m)
Debt / FCF = -0.01 (negative FCF - burning cash) (Net Debt 822k / FCF TTM -65.1m)
Total Stockholder Equity = 67.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -61.83% (Net Income -70.1m / Total Assets 126.3m)
RoE = -104.2% (Net Income TTM -70.1m / Total Stockholder Equity 67.3m)
RoCE = -54.94% (EBIT -56.5m / Capital Employed (Equity 67.3m + L.T.Debt 35.6m))
RoIC = -43.54% (negative operating profit) (NOPAT -44.6m / Invested Capital 102.5m)
WACC = 11.54% (E(274.0m)/V(315.4m) * Re(11.03%) + D(41.4m)/V(315.4m) * Rd(18.92%) * (1-Tc(0.21)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.47%
[DCF] Fair Price = unknown (Cash Flow -65.1m)
EPS Correlation: -63.81 | EPS CAGR: -72.34% | SUE: -2.40 | # QB: 0
Revenue Correlation: 79.21 | Revenue CAGR: 59.40% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.72 | Chg7d=-0.013 | Chg30d=-0.109 | Revisions Net=-5 | Analysts=7
EPS current Year (2026-12-31): EPS=-2.87 | Chg7d=+0.000 | Chg30d=-0.491 | Revisions Net=-7 | Growth EPS=-72.9% | Growth Revenue=+70.4%
EPS next Year (2027-12-31): EPS=-2.63 | Chg7d=-0.026 | Chg30d=-0.538 | Revisions Net=-6 | Growth EPS=+8.2% | Growth Revenue=+60.5%
[Analyst] Revisions Ratio: -0.71 (1 Up / 6 Down within 30d for Next Quarter)

Additional Sources for SENS Stock

Fund Manager Positions: Dataroma | Stockcircle